Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, John T. Vetto et al.|Journal of Clinical Oncology|2017Cited by 55
Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, Merrick I. Ross et al.|Journal of Clinical Oncology|2016Cited by 19